RCS - IP Group PLC - Enterprise reports positive results from P2 trial

IPAnnouncement

Tue 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260512:nRSL9659Da&default-theme=true

RNS Number : 9659D  IP Group PLC  12 May 2026

 FOR RELEASE ON  12 May 2026

Portfolio company Enterprise Therapeutics reports positive results

from Phase 2 clinical trial for cystic fibrosis

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in
breakthrough science and technology companies with the potential to create a
better future for all, notes that portfolio company Enterprise Therapeutics
Ltd ("Enterprise") has announced positive results from its Phase 2 trial for
ETD001, its lead candidate for the treatment of cystic fibrosis.

The Phase 2 trial evaluated the efficacy, safety, tolerability and
pharmacokinetics of inhaled ETD001 in the 10% of people with cystic fibrosis
with the highest unmet medical need and achieved its primary efficacy outcome.

The data demonstrated a clinically meaningful improvement in lung function
over a 28-day period compared to placebo. The results also showed that ETD001
is overall well-tolerated with adverse events consistent with those expected
in this patient population.

Enterprise has outlined plans to advance ETD001 into longer‑duration Phase
2b studies and in combination with CFTR modulator therapies, which are
effective for some but not all people with cystic fibrosis, and in other
muco‑obstructive lung diseases where high unmet need remains.

Greg Smith, Chief Executive of IP Group, said: "This is a highly encouraging
clinical milestone for Enterprise Therapeutics and a strong validation of its
differentiated approach to cystic fibrosis. Demonstrating a clinically
meaningful improvement in lung function in a population with significant unmet
need highlights the potential of ETD001. For IP Group, this represents another
example of our model providing investors with access to differentiated deep
science opportunities."

For more information, please contact:

 

 IP Group plc                       www.ipgroupplc.com
 Liz Vaughan-Adams, Communications  +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Lewis Bendall-Craft                +44 (0) 7931 973950

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most
active UK based, early stage science and technology investor, we develop and
support some of the world's most exciting businesses in healthtech, deeptech
and cleantech. Including through Parkwalk, the UK's largest growth EIS fund
manager, we back world-changing innovation emerging in leading universities
and research institutions. Our specialist investment team combines sector
expertise with an international approach. Together we have a strong track
record of success, having backed high-profile companies including Oxford
Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion,
Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock
Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

ENDS

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUURWRNBUVARR



            Copyright 2019 Regulatory News Service, all rights reserved